MannKind (NASDAQ:MNKD) shares are down 5.54% at $5.12 as of 9:44 a.m. EDT today. The fall appears related to concerns about Afrezza IMS script data. According to the IMS, Afrezza total scripts were down 0.3% wk/wk.

For comparison, here are the Rx metrics for relevant competitors: Humalog total scripts were down 1.6% wk/wk. Novolog total scripts were down 2.2% wk/wk. Apidra total scripts were up 1.2% wk/wk.

MNKD has a 1-year high of $10.08 and a 1-year low of $3.46. The stock’s 50-day moving average is $5.74 and its 200-day moving average is $5.54.

On the ratings front, MannKind has been the subject of a number of recent research reports. In a report issued on June 12, RBC analyst Adnan Butt maintained a Buy rating on MNKD. Separately, on June 9, Jefferies Co.’s Shaunak Deepak reiterated a Buy rating on the stock and has a price target of $9.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Adnan Butt and Shaunak Deepak have a total average return of -1.9% and -5.7% respectively. Butt has a success rate of 50.0% and is ranked #3056 out of 3714 analysts, while Deepak has a success rate of 33.3% and is ranked #3019.

Overall, one research analyst has rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and 2 analysts have given a Buy rating to the MNKD. When considering if perhaps the stock is under or overvalued, the average price target is $4.50 which is 17% under where the stock closed yesterday.

MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.